INNV earnings analysis
What we found in INNV's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
InnovAge delivered a significant fiscal 2026 recovery, with revenue up 15.9%, operating income turning positive at $2.618 million, and Adjusted EBITDA margin expanding to 9.6%. The PACE platform continues to scale, reaching approximately 8,230 participants across 20 centers, while operating cash flow nearly doubled to $64.714 million. However, the improvement remains exposed to $37.0 million of accrued litigation, anticipated Medicaid rate reductions that management expects to pressure fiscal 2027 margins, and California restrictions on new-center expansion.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Double-digit capitation-led growth
- Revenue increased 15.9% to $989.707 million in fiscal 2026 from $853.699 million in fiscal 2025. Capitation revenue rose 16.0% to $988.384 million, driven by a 7.8% increase in member months and a 7.6% increase in capitation rates.
- Near break-even GAAP results
- Operating income improved to $2.618 million from a $29.761 million operating loss, while net loss attributable to InnovAge narrowed to $2.537 million, or $0.02 diluted loss per share, from $30.313 million, or $0.22 per share.
- Material operating leverage
- Adjusted EBITDA increased 174% to $94.571 million, and Adjusted EBITDA margin expanded to 9.6% from 4.0%. Center-level Contribution Margin rose to $227.764 million, or 23.0% of revenue, from $153.639 million, or 18.0%.
- Scaled PACE platform
- The company served approximately 8,230 PACE participants as of June 30, 2026, making it the largest U.S. PACE provider by participants served, and operated 20 centers across six states and 14 markets.
- Stronger cash generation
- Operating cash flow increased to $64.714 million from $32.866 million. Cash and cash equivalents rose to $97.891 million from $64.129 million after $14.309 million of property and equipment purchases.
- External cost performance improved
- External provider cost per participant decreased 3.2%, while external provider costs grew 4.3% to $449.843 million despite a 7.8% increase in member months, reflecting lower nursing-facility utilization and pharmacy cost savings from in-house pharmacy services.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Large unresolved litigation exposure
- Litigation became a materially larger financial exposure: fiscal 2026 litigation expense included $56.966 million of charges, including $52.4 million accrued for potential resolutions or paid settlements. The balance-sheet litigation accrual was approximately $37.0 million at June 30, 2026, substantially related to DOJ and Colorado Medicaid False Claims Act matters.
- Medicaid rate pressure
- Management expects Medicaid reimbursement pressure in fiscal 2027, including a retroactive decrease in Medicaid premium rates in Colorado, the company’s largest census cohort, and potential California rate pressure beginning January 1, 2027. The company states these pressures are expected to affect fiscal 2027 margins.
- California expansion constrained
- California’s DHCS paused applications for all new PACE centers for a minimum of two years beginning November 20, 2025. DHCS also suspended attestations for planned Downey and Bakersfield centers after Sacramento and San Bernardino compliance issues; the company withdrew its Downey application in July 2026 and continues to pursue Bakersfield subject to remediation.
- Leverage and covenant constraints
- The company had $48.812 million of Term Loan A debt outstanding at June 30, 2026, with a variable interest rate of 6.15% and $94.797 million of total long-term debt and lease obligations. The credit agreement also restricts dividends, equity transactions, capital expenditures and permitted investments.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.02
- Operating margin
- 0.26%
- Segment
- PACE: $989.450 million of revenue and $227.640 million of Center-level Contribution Margin in fiscal 2026; the company operates as one reportable segment.
- Segment
- Other/Senior Housing: $0.257 million of revenue and $0.124 million of Center-level Contribution Margin; the remaining Senior Housing assets were sold.
What they said about what is next.
The 10-K does not provide quantitative fiscal 2027 revenue or EPS guidance; annual outlook was provided in the fiscal 2026 earnings release / call.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- InnovAge Holding Corp. reported strong revenue growth in Q3 FY2026, with total revenues reaching $251.943 million, a 15.5% increase from the prior year. However, the company experienced a net loss of $29.9 million,…
- 10-Q · November 4, 2025
- InnovAge reported Q1 revenue of $236.105M and GAAP diluted EPS of $0.06 for the three months ended September 30, 2025, compared with $205.142M revenue and $(0.04) EPS in the year-ago quarter. The quarter delivered…
- 10-K · September 9, 2025
- InnovAge describes a scale-driven, vertically integrated PACE (fully capitated) care model focused on frail, dual-eligible seniors and served approximately 7,740 participants across 20 centers as of June 30, 2025. The…
- 10-Q · November 5, 2024
- InnovAge reported revenue of $205,142,000 for the quarter ended September 30, 2024, up $22,657,000 (+12.4%) versus the prior-year quarter, with an improved operating loss of $(4,896,000) (vs. $(10,718,000) a year ago)…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing INNV makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever